Anti-CD3 Antibody CDR Sequence Engineering for Binding Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-CD3 antibodies lack unique binding characteristics and specificity for targeting epitopes, limiting their effectiveness in treating cancer and autoimmune diseases.
Innovation Solution
Development of novel anti-CD3 antibodies with specific heavy and light chain variable domain complementarity determining regions (CDR) sequences that enhance binding affinity and specificity, including monoclonal, bispecific, multivalent, and multi-specific formats, to trigger immune activation or tolerance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional anti-CD3 antibodies are used, then basic T cell activation can be achieved, but binding specificity and affinity for target epitopes are insufficient
Solution Approach 1:
The patent applies parameter changes by systematically modifying the CDR sequences of the antibody variable domains. Specific amino acid residues at defined positions in CDR1, CDR2, and CDR3 regions are changed to create novel binding specificities. This allows the antibody to target specific epitopes on CD3 with high affinity while maintaining T cell activation capability, thereby resolving the contradiction between binding precision and therapeutic reliability.
Solution Approach 2:
The patent applies local quality by focusing mutations and optimizations specifically in the complementarity determining regions (CDR1, CDR2, CDR3) of the antibody variable domains. By concentrating changes in these critical local regions rather than the entire antibody structure, the invention achieves enhanced binding specificity to particular CD3 epitopes while preserving the overall antibody function and therapeutic efficacy.
2Adaptability or versatility
If existing anti-CD3 antibodies are used, then immune activation can be triggered, but lack of unique binding characteristics limits treatment effectiveness
Solution Approach 1:
The patent applies segmentation by dividing the antibody variable domain into distinct complementarity determining regions (CDR1, CDR2, CDR3), each responsible for specific binding interactions. By independently optimizing each segment's sequence and structure, the invention achieves precise epitope targeting and high binding affinity. This segmented approach allows tailored binding characteristics for different therapeutic applications while maintaining manufacturability through modular design.
3Measurement precision
If novel anti-CD3 antibodies with specific CDR sequences are developed, then binding affinity and specificity are enhanced, but development complexity increases
Solution Approach 1:
The patent applies parameter changes by implementing systematic mutations at specific amino acid positions within the CDR regions rather than creating entirely new antibody structures. By modifying defined parameters (amino acid sequences at specific positions) within the framework of known antibody structures, the invention achieves enhanced binding affinity while controlling structural complexity. This approach maintains manufacturability and reduces development complexity compared to de novo antibody design.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel anti-CD3 antibodies demonstrate improved binding capabilities and therapeutic efficacy in treating autoimmune diseases and cancer by triggering targeted immune responses.
Implementation Method 1
an anti-CD3 antibody, wherein the antibody comprises: a heavy chain variable domain (VH) complementarity determining region 1 (CDR1) comprising the amino acid sequence of any one of the following SEQ ID NOs
Data Source
AI summary
Provided herein are novel human anti-CD3 antigen-binding polypeptides, treatments, nucleic acids, vectors, their preparation and their use in the treatment and/or diagnosis of various diseases, and also relates to bispecific antibody molecules capable of activating immune effector cells and their use in diagnosis and/or treatment of various diseases.